Post-earnings recap
Reported
Tue, Feb 3, 2026
Est. EPS
$6.96
Est. revenue
$72.0B
Implied move
±7.2%
EPS beat rate
63%
Novo Nordisk A/S is a leading global healthcare company specializing in pharmaceuticals, particularly in diabetes care and hormone replacement therapies. With a market cap of $197 billion, it plays a crucial role in addressing chronic health conditions, making it significant in the healthcare sector.
Last quarter
In Q3-2025, Novo Nordisk reported an EPS of $0.69, falling short of the expected $0.77, resulting in a 10.1% surprise. The stock reacted positively the following day, gaining 0.44%.
EPS beat streak
2Q
EPS beat rate
63%
Avg EPS surprise
+39.05%
Avg 1-day reaction
-0.99%
Analysts are cautiously optimistic about Novo Nordisk's upcoming earnings, with expectations of strong EPS and revenue figures. However, the company has shown mixed results in recent quarters, leading to uncertainty.
Bull case
If Novo Nordisk exceeds EPS expectations, it could signal robust demand for its diabetes and hormone therapies, potentially boosting investor confidence.
Bear case
A miss on EPS or revenue could raise concerns about market competition and pricing pressures, which may negatively impact the stock.
Key metrics to watch
EPS
$6.96Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$72.0BTotal revenue reflects the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will the EPS exceed the consensus estimate of $6.96?
A beat on EPS could indicate strong operational performance and boost investor sentiment.
Q2
What are the revenue projections compared to the consensus of $72.0B?
Revenue figures will provide insight into market demand and the company's competitive position in the pharmaceutical sector.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Why consensus could be wrong
The consensus may underestimate the potential for Novo Nordisk to outperform due to its strong product pipeline and market leadership in diabetes care.
Supporting evidence
Recent performance trends suggest a growing demand for diabetes medications, which could drive revenue higher than expected.
Options pricing indicates a significant move, suggesting that the market is not fully pricing in potential upside.
Key risk
If the company can demonstrate strong demand for its diabetes products, it could significantly outperform current revenue expectations.
Pre-commit to what would confirm each case.
This quarter's results will be pivotal in assessing the company's growth trajectory and market position.
Bull confirmed if
EPS exceeding $6.96 with revenue above $72.0B would confirm a strong operational performance.
Bear confirmed if
EPS below $6.96 and revenue falling short of $72.0B would indicate potential challenges in the market.
What the market is pricing for the move.
Implied Move
±7.42%
Historical Avg
±3.76%
The options market is pricing in a significant move around the earnings report, indicating heightened investor uncertainty.
Options price a 7.42% move but the stock has averaged only 3.76% over the last 8 quarters — setup is rich.
ATM IV
1.0%
30d HV
35.5%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
Fade rate: 4 of 18 (22%)
This setup has occurred 30 times across Health Care in the last 2 years. 14 of 18 (78%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 6.8%, with a raw directional average of +3.0% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
9.89%
of float
Insider
0.00%
of float
Holders
1,605
institutions
Top Holders· as of Jun 2026
Dodge & Cox Inc.
20,397,110 sh · $780.4M
0.60%
5.5%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Novo Nordisk beats expectations, history suggests the stock could rise by around 0.22% on average the following day, confirming positive market sentiment.
In line / cautious
An in-line report may lead to muted reactions, as management commentary could drive uncertainty.
Miss
If the company misses expectations, history suggests a potential decline of about 4.09% on average the following day, reflecting investor disappointment.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
3
1 buy·2 sells
Members
2
House only
Est. Notional
$3,003.00–$45,000.00
disclosed dollar ranges
Most Active Members
2 trades
The lines on the call that would change the story.
LOOMIS SAYLES & CO L P
18,594,352 sh · $711.4M
0.55%
9.3%
Franklin Resources, Inc.
13,041,109 sh · $499.0M
0.38%
-18.9%
Price (T.Rowe) Associates Inc
11,704,719 sh · $447.8M
0.35%
5.8%
Morgan Stanley
11,659,869 sh · $446.1M
0.34%
7.3%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
1 trade
Net buying
Recent Transactions
Traded Sep 10, 2026 · disclosed Sep 25, 2026
$1,001.00–$15,000.00
Traded Aug 31, 2026 · disclosed Sep 25, 2026
$1,001.00–$15,000.00
Traded Aug 26, 2026 · disclosed Sep 17, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.